What Does Polmed SA’s (WSE:POM) PE Ratio Tell You?

This analysis is intended to introduce important early concepts to people who are starting to invest and want to start learning about core concepts of fundamental analysis on practical examples from today’s market.

Polmed SA (WSE:POM) trades with a trailing P/E of 11.2x, which is lower than the industry average of 12x. While this makes POM appear like a great stock to buy, you might change your mind after I explain the assumptions behind the P/E ratio. In this article, I will explain what the P/E ratio is as well as what you should look out for when using it.

See our latest analysis for Polmed

What you need to know about the P/E ratio

WSE:POM PE PEG Gauge July 31st 18
WSE:POM PE PEG Gauge July 31st 18

P/E is often used for relative valuation since earnings power is a chief driver of investment value. It compares a stock’s price per share to the stock’s earnings per share. A more intuitive way of understanding the P/E ratio is to think of it as how much investors are paying for each dollar of the company’s earnings.

Formula

Price-Earnings Ratio = Price per share ÷ Earnings per share

P/E Calculation for POM

Price per share = PLN2.9

Earnings per share = PLN0.259

∴ Price-Earnings Ratio = PLN2.9 ÷ PLN0.259 = 11.2x

The P/E ratio itself doesn’t tell you a lot; however, it becomes very insightful when you compare it with other similar companies. We preferably want to compare the stock’s P/E ratio to the average of companies that have similar features to POM, such as capital structure and profitability. A quick method of creating a peer group is to use companies in the same industry, which is what I will do. Since similar companies should technically have similar P/E ratios, we can very quickly come to some conclusions about the stock if the ratios differ.

Since POM’s P/E of 11.2x is lower than its industry peers (12x), it means that investors are paying less than they should for each dollar of POM’s earnings. This multiple is a median of profitable companies of 6 Healthcare companies in PL including Swissmed Centrum Zdrowia, Polski Bank Komórek Macierzystych and Dent-a-Medical. As such, our analysis shows that POM represents an under-priced stock.

Assumptions to watch out for

While our conclusion might prompt you to buy POM immediately, there are two important assumptions you should be aware of. The first is that our “similar companies” are actually similar to POM. If the companies aren’t similar, the difference in P/E might be a result of other factors. For example, if you are inadvertently comparing lower risk firms with POM, then POM’s P/E would naturally be lower than its peers, since investors would value those with lower risk with a higher price. The other possibility is if you were accidentally comparing higher growth firms with POM. In this case, POM’s P/E would be lower since investors would also reward its peers’ higher growth with a higher price. The second assumption that must hold true is that the stocks we are comparing POM to are fairly valued by the market. If this assumption does not hold true, POM’s lower P/E ratio may be because firms in our peer group are being overvalued by the market.

WSE:POM Future Profit July 31st 18
WSE:POM Future Profit July 31st 18

What this means for you:

Since you may have already conducted your due diligence on POM, the undervaluation of the stock may mean it is a good time to top up on your current holdings. But at the end of the day, keep in mind that relative valuation relies heavily on critical assumptions I’ve outlined above. Remember that basing your investment decision off one metric alone is certainly not sufficient. There are many things I have not taken into account in this article and the PE ratio is very one-dimensional. If you have not done so already, I highly recommend you to complete your research by taking a look at the following:

  1. Future Outlook: What are well-informed industry analysts predicting for POM’s future growth? Take a look at our free research report of analyst consensus for POM’s outlook.
  2. Past Track Record: Has POM been consistently performing well irrespective of the ups and downs in the market? Go into more detail in the past performance analysis and take a look at the free visual representations of POM’s historicals for more clarity.
  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.